Alaunos Therapeutics, Inc.

1.18 USD
+0.06 (+5.36%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Alaunos Therapeutics, Inc. stock is up 8.26% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 36.84% of the previous 18 May’s closed higher than April.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR. The company was formerly known as ZIOPHARM Oncology, Inc.